---
brand_name: "OMNICEF"
generic_name: "CEFDINIR"
slug: "cefdinir-iscontinued-or-wit-1"
canonical_url: "https://medichelpline.com/drug-index/cefdinir-iscontinued-or-wit-1"
content_type: "drug_monograph"
route: "ORAL"
drug_class: "General Medications"
fda_updated_at: "2015-11-18T00:00:00.000Z"
license: "Drugs@FDA Public Domain / Informational Use"
---
# OMNICEF (CEFDINIR)
## Clinical Monograph Metadata
- **Canonical URL:** https://medichelpline.com/drug-index/cefdinir-iscontinued-or-wit-1
- **Generic / Active Ingredient:** CEFDINIR
- **Brand Name:** OMNICEF
- **Administration Route:** ORAL
- **Pharmacological Class:** General Medications
- **FDA Data Timestamp:** 2015-11-18T00:00:00.000Z
## Primary Indication & Clinical Use
Please see www.fda.gov/STIC for labeling requirements on susceptibility test interpretive criteria for systemic antibacterial and antifungal drugs. Review priority: STANDARD Marketing status: Discontinued
## Monograph Summary

Approval overview OMNICEF is listed in Drugs@FDA under application 050749 (NDA). Please see www.fda.gov/STIC for labeling requirements on susceptibility test interpretive criteria for systemic antibacterial and antifungal drugs. Review priority: STANDARD Marketing status: Discontinued Active ingredient CEFDINIR Form and strength FOR SUSPENSION;ORAL - 250MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor ABBVIE Submission history Latest submission status date: 2015-11-18 00:00:00. Submission type: SUPPL.

## Primary Sources & FDA Regulatory Records
- [Drugs@FDA Primary Database](https://www.accessdata.fda.gov/scripts/cder/daf/) (Reference Slug: `cefdinir-iscontinued-or-wit-1`)
## Navigation
- [← Back to Drug Index Hub](https://medichelpline.com/drug-index.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.